Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks

Abstract Background Symptoms of hereditary angioedema (HAE) attacks can recur soon after initial treatment; the durability of response for recombinant human C1 esterase inhibitor (rhC1INH) treatment is unknown. Objective To examine the efficacy and durability of rhC1INH for acute HAE attacks. Method...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of allergy, asthma, & immunology asthma, & immunology, 2017-04, Vol.118 (4), p.452-455
Hauptverfasser:	Bernstein, Jonathan A., MD, Relan, Anurag, MD, Harper, Joseph R., PharmD, Riedl, Marc, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Allergy and Immunology Complement C1 Inhibitor Protein - administration & dosage Complement C1 Inhibitor Protein - therapeutic use Disease Progression Female Hereditary Angioedema Types I and II - drug therapy Humans Male Middle Aged Recombinant Proteins - administration & dosage Recombinant Proteins - therapeutic use Recurrence Time-to-Treatment Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background Symptoms of hereditary angioedema (HAE) attacks can recur soon after initial treatment; the durability of response for recombinant human C1 esterase inhibitor (rhC1INH) treatment is unknown. Objective To examine the efficacy and durability of rhC1INH for acute HAE attacks. Methods In this pooled post hoc analysis of 2 trials, patients with type I or II HAE (functional C1INH levels
ISSN:	1081-1206 1534-4436
DOI:	10.1016/j.anai.2017.01.029